Actually, the company already disclosed they are jumping into (2) pivotal, phase2/3 trials for rare diseases. One of those is Fragile X and the other is undisclosed. Technically, they are setting themselves up for 2 more approvals if they can measure improvement in these indications.
The key here is they are cutting out years of development time from these rare diseases - BASED ON THE RESULTS FROM 1 TRIAL. This accomplishment certainly didnt get the recognition it deserved, imo.
Market Data 
Markets 
AI
